Skip to content

Study · Not a test of the peptide alone · 2026

4 results

Improvement of aphasia deficits following traumatic intracranial hemorrhage: a case report.

Choi J

Journal of medicine and life1 Jul 2026

PMID42751610 (opens in a new tab)DOI10.25122/jml-2026-0072 (opens in a new tab)PepBankPUB-42751610
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

Aphasia is a common and disabling consequence of dominant-hemisphere brain injury, and the pharmacological options after traumatic intracranial hemorrhage are limited. A 69-year-old man developed severe aphasia after traumatic intracranial hemorrhage. On day 7 after traumatic brain injury (TBI), he was transferred for inpatient rehabilitation, where the Korean version of the Western Aphasia Battery (K-WAB) showed marked language impairment, with an Aphasia Quotient (AQ) of 66.2 (scale 0-100; higher scores indicate better language function). He received intravenous Cerebrolysin, 30 mL/day infused over 60 minutes, for 21 consecutive days, together with daily speech-language therapy. By day 28, the AQ had risen to 97.1, with gains in both expressive and receptive language, and no adverse events were recorded. Spontaneous subacute recovery and the concurrent speech-language therapy may account for the change, and a single patient cannot establish an effect; the time course and the size of the change nonetheless raise the possibility of an adjunctive neurorestorative contribution from Cerebrolysin in post-traumatic hemorrhagic aphasia. Controlled studies in TBI populations are needed.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study4

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone4

In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Cerebrolysin.

  1. 01HumanNot a test of Cerebrolysin aloneCase report or seriesEfficacy outcome

    In a man with traumatic hemorrhagic aphasia, Aphasia Quotient increased during Cerebrolysin and daily speech-language therapy.

    In plain wordsIn a man with traumatic hemorrhagic aphasia, Aphasia Quotient increased during Cerebrolysin and daily speech-language therapy.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseAphasia Quotient
    Study

    n = 1

    Outcome group
    Cognition and memory · Nervous system and cognition

    Measurements

    Aphasia Quotient
    66.2
    day 7
    Aphasia Quotient
    97.1
    day 28

    Source sentences

    Summary
    By day 28, the AQ had risen to 97.1, with gains in both expressive and receptive language, and no adverse events were recorded.
    2 context sentences
    Summary · context
    He received intravenous Cerebrolysin, 30 mL/day infused over 60 minutes, for 21 consecutive days, together with daily speech-language therapy.
    Summary · context
    On day 7 after traumatic brain injury (TBI), he was transferred for inpatient rehabilitation, where the Korean version of the Western Aphasia Battery (K-WAB) showed marked language impairment, with an Aphasia Quotient (AQ) of 66.2 (scale 0-100; higher scores indicate better language function).

    In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cerebrolysin.

  2. 02HumanNot a test of Cerebrolysin aloneCase report or seriesEfficacy outcome

    In a man with traumatic hemorrhagic aphasia, expressive language improved during Cerebrolysin and daily speech-language therapy.

    In plain wordsIn a man with traumatic hemorrhagic aphasia, expressive language improved during Cerebrolysin and daily speech-language therapy.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseExpressive language
    Study

    n = 1

    Outcome group
    Cognition and memory · Nervous system and cognition

    Source sentences

    Summary
    By day 28, the AQ had risen to 97.1, with gains in both expressive and receptive language, and no adverse events were recorded.
    1 context sentence
    Summary · context
    He received intravenous Cerebrolysin, 30 mL/day infused over 60 minutes, for 21 consecutive days, together with daily speech-language therapy.

    In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cerebrolysin.

  3. 03HumanNot a test of Cerebrolysin aloneCase report or seriesEfficacy outcome

    In a man with traumatic hemorrhagic aphasia, receptive language improved during Cerebrolysin and daily speech-language therapy.

    In plain wordsIn a man with traumatic hemorrhagic aphasia, receptive language improved during Cerebrolysin and daily speech-language therapy.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseReceptive language
    Study

    n = 1

    Outcome group
    Cognition and memory · Nervous system and cognition

    Source sentences

    Summary
    By day 28, the AQ had risen to 97.1, with gains in both expressive and receptive language, and no adverse events were recorded.
    1 context sentence
    Summary · context
    He received intravenous Cerebrolysin, 30 mL/day infused over 60 minutes, for 21 consecutive days, together with daily speech-language therapy.

    In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cerebrolysin.

  4. 04HumanNot a test of Cerebrolysin aloneCase report or seriesSafety outcome

    In a man with traumatic hemorrhagic aphasia, no adverse events were recorded during Cerebrolysin and speech-language therapy.

    In plain wordsIn a man with traumatic hemorrhagic aphasia, no adverse events were recorded during Cerebrolysin and speech-language therapy.

    Peptide
    Cerebrolysin
    Outcome
    Not applicableAdverse events
    Study

    n = 1

    Outcome group
    Adverse events · Whole body

    Source sentences

    Summary
    By day 28, the AQ had risen to 97.1, with gains in both expressive and receptive language, and no adverse events were recorded.
    1 context sentence
    Summary · context
    He received intravenous Cerebrolysin, 30 mL/day infused over 60 minutes, for 21 consecutive days, together with daily speech-language therapy.

    In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cerebrolysin.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.